Recent Company News

• 06:21 PM ET May 13, 2026
  

  Sino Biopharmaceutical provides pre-clinical data for TQF6422 at ECO 2026 (HK$5.65, 0.00)

• 12:16 AM ET May 11, 2026
  

  Sino Biopharmaceutical subsidiary enters into exclusive strategic collaboration with GlaxoSmithKline to accelerate bepirovirsen in China at launch (HK$5.53, +0.10)

• 04:46 AM ET May 07, 2026
  

  NDA from Sino Biopharmaceutical's subsidiary for M701 "CD3/EpCAM Bispecific Antibody" accepted by NMPA (HK$5.46, 0.00)

• 06:51 PM ET May 06, 2026
  

  Sino Biopharmaceutical enrols first patient in Phase III clinical trial of cafelkibart "CCR8 Monoclonal Antibody" LM-108 (HK$5.40, 0.00)

• 05:04 AM ET May 06, 2026
  

  NMPA approves marketing of Sino Biopharmaceutical's culmerciclib combined with fulvestrant for initial endocrine therapy for HR-postiive, HER2-negative breast cancer (HK$5.40, 0.00)

• 09:36 PM ET May 05, 2026
  

  StreetAccount Sector Summary - China Healthcare April Recap

• 05:05 AM ET Apr 29, 2026
  

  Sino Biopharmaceutical releases 2025 ESG report (HK$5.46, 0.00)

• 07:24 PM ET Apr 23, 2026
  

  Sino Biopharmaceutical initiated overweight at Northeast Securities (timing uncertain)

• 06:21 PM ET Apr 21, 2026
  

  Sino Biopharmaceutical presents clinical data for LM-364 and LM-338 at AACR 2026 (HK$5.82, 0.00)

• 04:56 AM ET Apr 20, 2026
  

  NMPA approves marketing of combination treatment of Sino Biopharmaceutical's benmelstobart and anlotinib for ASPS (HK$5.95, 0.00)